Kan S et al. |
Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells. |
2015 |
BMC Cancer |
pmid:26475267
|
Montero JC et al. |
Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling. |
2015 |
Oncotarget |
pmid:26336133
|
Gébleux R et al. |
Antibody Format and Drug Release Rate Determine the Therapeutic Activity of Noninternalizing Antibody-Drug Conjugates. |
2015 |
Mol. Cancer Ther. |
pmid:26294742
|
Storz U |
Antibody-drug conjugates: Intellectual property considerations. |
2015 |
MAbs |
pmid:26292154
|
Nguyen M et al. |
Preclinical Efficacy and Safety Assessment of an Antibody-Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma. |
2015 |
Clin. Cancer Res. |
pmid:26240273
|
Chung YC et al. |
Caveolin-1 Dependent Endocytosis Enhances the Chemosensitivity of HER-2 Positive Breast Cancer Cells to Trastuzumab Emtansine (T-DM1). |
2015 |
PLoS ONE |
pmid:26172389
|
Beerli RR et al. |
Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency. |
2015 |
PLoS ONE |
pmid:26132162
|
van Geel R et al. |
Chemoenzymatic Conjugation of Toxic Payloads to the Globally Conserved N-Glycan of Native mAbs Provides Homogeneous and Highly Efficacious Antibody-Drug Conjugates. |
2015 |
Bioconjug. Chem. |
pmid:26061183
|
Miranda Romero P and MarÃn Gil R |
Trastuzumab emtansine in locally advanced or metastatic HER2 positive breast cancer; GENESIS-SEFH drug evaluation report. |
2015 |
Farm Hosp |
pmid:26005893
|
Esteva FJ et al. |
What Can We Learn about Antibody-Drug Conjugates from the T-DM1 Experience? |
2015 |
Am Soc Clin Oncol Educ Book |
pmid:25993162
|
Hamblett KJ et al. |
AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma. |
2015 |
Mol. Cancer Ther. |
pmid:25931519
|
Yabe N et al. |
[A Case of Advanced Breast Cancer in Which Marked Improvement of Joint Pain Was Obtained with Stepwise Dose Reduction of Trastuzumab Emtansine (T-DM1)]. |
2015 |
Gan To Kagaku Ryoho |
pmid:26805183
|
Müller P et al. |
Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade. |
2015 |
Sci Transl Med |
pmid:26606967
|
Eisenstein M |
Medicine: Eyes on the target. |
2015 |
Nature |
pmid:26580159
|
Mustacchi G et al. |
HER2-positive metastatic breast cancer: a changing scenario. |
2015 |
Crit. Rev. Oncol. Hematol. |
pmid:25748080
|
Salomon PL and Singh R |
Sensitive ELISA Method for the Measurement of Catabolites of Antibody-Drug Conjugates (ADCs) in Target Cancer Cells. |
2015 |
Mol. Pharm. |
pmid:25738394
|
Fishkin N |
Maytansinoid-BODIPY Conjugates: Application to Microscale Determination of Drug Extinction Coefficients and for Quantification of Maytansinoid Analytes. |
2015 |
Mol. Pharm. |
pmid:25738231
|
Goldmacher VS et al. |
Statistics of the distribution of the abundance of molecules with various drug loads in maytansinoid antibody-drug conjugates. |
2015 |
Mol. Pharm. |
pmid:25635630
|
Ahmed S et al. |
HER2-directed therapy: current treatment options for HER2-positive breast cancer. |
2015 |
Breast Cancer |
pmid:25634227
|
Foglietta J et al. |
Letter to the editor concerning 'Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA'. |
2015 |
Ann. Oncol. |
pmid:25632067
|
Wiggins B et al. |
Characterization of cysteine-linked conjugation profiles of immunoglobulin G1 and immunoglobulin G2 antibody-drug conjugates. |
2015 |
J Pharm Sci |
pmid:25631158
|
Lai KC et al. |
Evaluation of Targets for Maytansinoid ADC Therapy Using a Novel Radiochemical Assay. |
2015 |
Pharm. Res. |
pmid:25630819
|
Li T et al. |
Improvement of ansamitocin P-3 production by Actinosynnema mirum with fructose as the sole carbon source. |
2015 |
Appl. Biochem. Biotechnol. |
pmid:25564203
|
Carneiro BA et al. |
Emerging therapeutic targets in bladder cancer. |
2015 |
Cancer Treat. Rev. |
pmid:25498841
|
Baron JM et al. |
Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer. |
2015 |
J Oncol Pharm Pract |
pmid:24682654
|
Whiteman KR et al. |
Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models. |
2014 Mar-Apr |
MAbs |
pmid:24492307
|
Tanz R et al. |
[Towards an integrated approach to cardiovascular toxicities related to the treatments of breast cancer]. |
2014 Jul-Aug |
Bull Cancer |
pmid:25091656
|
Panowski S et al. |
Site-specific antibody drug conjugates for cancer therapy. |
2014 Jan-Feb |
MAbs |
pmid:24423619
|
Beck A and Reichert JM |
Antibody-drug conjugates: present and future. |
2014 Jan-Feb |
MAbs |
pmid:24423577
|
Lieberman P and Castells M |
Desensitization to chemotherapeutic agents. |
2014 Jan-Feb |
J Allergy Clin Immunol Pract |
pmid:24565784
|
Bartsch R et al. |
Breast cancer brain metastases responding to primary systemic therapy with T-DM1. |
2014 |
J. Neurooncol. |
pmid:24065570
|
Ribrag V et al. |
A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. |
2014 |
Clin. Cancer Res. |
pmid:24132920
|
Krop I and Winer EP |
Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer. |
2014 |
Clin. Cancer Res. |
pmid:24135146
|
Krop IE et al. |
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. |
2014 |
Lancet Oncol. |
pmid:24793816
|
Gnant M et al. |
HER2-positive breast cancer: a new piece of the puzzle. |
2014 |
Lancet Oncol. |
pmid:24793817
|
Montemurro F |
HER2 expression and efficacy of T-DM1. |
2014 |
Breast Cancer Res. |
pmid:25472666
|
Vigne E and Sassoon I |
[The growing field of immunoconjugates in oncology. A successful link(er) between antibodies and small cytotoxic molecules]. |
2014 |
Med Sci (Paris) |
pmid:25311020
|
Feng L et al. |
Efficacy of anti-RON antibody Zt/g4-drug maytansinoid conjugation (Anti-RON ADC) as a novel therapeutics for targeted colorectal cancer therapy. |
2014 |
Clin. Cancer Res. |
pmid:25294907
|
Field JJ et al. |
A previously undescribed tubulin binder. |
2014 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:25187564
|
Welslau M et al. |
Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer. |
2014 |
Cancer |
pmid:24222194
|
Gibiansky L and Gibiansky E |
Target-mediated drug disposition model and its approximations for antibody-drug conjugates. |
2014 |
J Pharmacokinet Pharmacodyn |
pmid:24322877
|
Kim M et al. |
Updates on the treatment of human epidermal growth factor receptor type 2-positive breast cancer. |
2014 |
Curr. Opin. Obstet. Gynecol. |
pmid:24335887
|
Miller KD et al. |
Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer. |
2014 |
J. Clin. Oncol. |
pmid:24733796
|
Kusari S et al. |
Endophytes are hidden producers of maytansine in Putterlickia roots. |
2014 |
J. Nat. Prod. |
pmid:25478947
|
Fan Y et al. |
Process optimization with alternative carbon sources and modulation of secondary metabolism for enhanced ansamitocin P-3 production in Actinosynnema pretiosum. |
2014 |
J. Biotechnol. |
pmid:25456055
|
Coussy F et al. |
[New targeted therapies in breast cancer]. |
2014 |
Gynecol Obstet Fertil |
pmid:25442825
|
Bhardwaj AS et al. |
A case of vasculitis in a breast cancer patient treated with T-DM1. |
2014 |
Semin. Oncol. |
pmid:25440614
|
Mancuso L et al. |
Preparation of thermocleavable conjugates based on ansamitocin and superparamagnetic nanostructured particles by a chemobiosynthetic approach. |
2014 |
Chemistry |
pmid:25346489
|
Teplinsky E and Muggia F |
Targeting HER2 in ovarian and uterine cancers: challenges and future directions. |
2014 |
Gynecol. Oncol. |
pmid:25220628
|
Pillow TH et al. |
Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering. |
2014 |
J. Med. Chem. |
pmid:25191794
|